IPP Bureau
AGC Pharma Chemicals opens new €100 million manufacturing plant in Spain
By IPP Bureau - October 06, 2025
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
India invites applications under PRIP scheme to drive pharma-medtech innovation
By IPP Bureau - October 06, 2025
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Lilly to invest $1 billion+ in new contract manufacturing in India
By IPP Bureau - October 06, 2025
Investment to expand manufacturing and global medicine supply capacity
Roche’s AI-based kidney disease algorithm gains European certification
By IPP Bureau - October 06, 2025
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
TAHO Pharma submits NDA to FDA for world’s first Apixaban oral dissolving film
By IPP Bureau - October 06, 2025
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Evofem's SOLOSEC submitted for regulatory approval in the UAE
By IPP Bureau - October 06, 2025
Marks first international filing for Evofem’s single-dose oral treatment
Nanavati Max, Uzbekistan’s NVRH forge alliance to advance healthcare and training
By IPP Bureau - October 06, 2025
Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection
By IPP Bureau - October 05, 2025
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer
By IPP Bureau - October 05, 2025
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
AbbVie’s Natrelle awarded supplier agreement from Vizient
By IPP Bureau - October 05, 2025
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease
By IPP Bureau - October 05, 2025
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda exits cell therapy research
By IPP Bureau - October 05, 2025
Takeda will seek an external partner to leverage its cell therapy platform technologies
Amgen’s Phase III data supports FDA label expansion of Repatha
By IPP Bureau - October 05, 2025
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
AstraZeneca Pharma India receives sale, distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder
By IPP Bureau - October 04, 2025
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Lupin launches Liraglutide injection in US
By IPP Bureau - October 04, 2025
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
